O	0	8	Adjuvant
B-intervention	9	21	Capecitabine
I-intervention	22	26	With
I-intervention	27	36	Docetaxel
I-intervention	37	40	and
I-intervention	41	57	Cyclophosphamide
I-intervention	58	62	Plus
I-intervention	63	73	Epirubicin
O	74	77	for
O	78	84	Triple
O	84	85	-
O	85	93	Negative
O	94	100	Breast
O	101	107	Cancer
O	108	109	(
O	109	117	CBCSG010
O	117	118	)
O	118	119	:
O	120	122	An
O	123	127	Open
O	127	128	-
O	128	133	Label
O	133	134	,
O	135	145	Randomized
O	145	146	,
O	147	158	Multicenter
O	158	159	,
O	160	165	Phase
O	166	169	III
O	170	175	Trial
O	175	176	.

O	177	185	Standard
O	186	194	adjuvant
O	195	207	chemotherapy
O	208	211	for
O	212	218	triple
O	218	219	-
O	219	227	negative
O	228	234	breast
O	235	241	cancer
O	242	243	(
O	243	247	TNBC
O	247	248	)
O	249	257	includes
O	258	259	a
O	260	266	taxane
O	267	270	and
O	271	273	an
O	274	287	anthracycline
O	287	288	.

O	289	300	Concomitant
O	301	313	capecitabine
O	314	317	may
O	318	320	be
O	321	331	beneficial
O	331	332	,
O	333	336	but
O	337	343	robust
O	344	348	data
O	349	351	to
O	352	359	support
O	360	364	this
O	365	368	are
O	369	376	lacking
O	376	377	.

O	378	381	The
O	382	390	efficacy
O	391	394	and
O	395	401	safety
O	402	404	of
O	405	408	the
O	409	417	addition
O	418	420	of
O	421	433	capecitabine
O	434	438	into
O	439	442	the
O	443	447	TNBC
O	448	456	adjuvant
O	457	466	treatment
O	467	474	regimen
O	475	478	was
O	479	488	evaluated
O	488	489	.

O	490	494	This
O	495	505	randomized
O	505	506	,
O	507	511	open
O	511	512	-
O	512	517	label
O	517	518	,
O	519	524	phase
O	525	528	III
O	529	534	trial
O	535	538	was
O	539	548	conducted
O	549	551	in
B-location	552	557	China
O	557	558	.

O	559	567	Eligible
B-eligibility	568	574	female
I-eligibility	575	583	patients
I-eligibility	584	588	with
I-eligibility	589	594	early
I-eligibility	595	599	TNBC
I-eligibility	600	605	after
I-eligibility	606	616	definitive
I-eligibility	617	624	surgery
O	625	629	were
O	630	638	randomly
O	639	647	assigned
O	648	649	(
O	649	650	1
O	650	651	:
O	651	652	1
O	652	653	)
O	654	656	to
O	657	663	either
O	664	676	capecitabine
O	677	678	(
O	678	679	3
O	680	686	cycles
O	687	689	of
O	690	702	capecitabine
O	703	706	and
O	707	716	docetaxel
O	717	725	followed
O	726	728	by
O	729	730	3
O	731	737	cycles
O	738	740	of
O	741	753	capecitabine
O	753	754	,
O	755	765	epirubicin
O	765	766	,
O	767	770	and
O	771	787	cyclophosphamide
O	787	788	)
O	789	791	or
B-control	792	799	control
I-control	800	809	treatment
O	810	811	(
O	811	812	3
O	813	819	cycles
O	820	822	of
O	823	832	docetaxel
O	833	841	followed
O	842	844	by
O	845	846	3
O	847	853	cycles
O	854	856	of
O	857	869	fluorouracil
O	869	870	,
O	871	881	epirubicin
O	881	882	,
O	883	886	and
O	887	903	cyclophosphamide
O	903	904	)
O	904	905	.

O	906	919	Randomization
O	920	923	was
O	924	935	centralized
O	936	943	without
O	944	958	stratification
O	958	959	.

O	960	963	The
O	964	971	primary
O	972	975	end
O	976	981	point
O	982	985	was
B-outcome-Measure	986	993	disease
I-outcome-Measure	993	994	-
I-outcome-Measure	994	998	free
I-outcome-Measure	999	1007	survival
I-outcome-Measure	1008	1009	(
I-outcome-Measure	1009	1012	DFS
I-outcome-Measure	1012	1013	)
O	1013	1014	.

O	1015	1022	Between
O	1023	1027	June
O	1028	1032	2012
O	1033	1036	and
O	1037	1045	December
O	1046	1050	2013
O	1050	1051	,
B-total-participants	1052	1055	636
O	1056	1064	patients
O	1065	1069	with
O	1070	1074	TNBC
O	1075	1079	were
O	1080	1088	screened
O	1088	1089	,
O	1090	1093	and
B-total-participants	1094	1097	585
O	1098	1102	were
O	1103	1111	randomly
O	1112	1120	assigned
O	1121	1123	to
O	1124	1133	treatment
O	1134	1135	(
O	1135	1142	control
O	1142	1143	,
B-control-participants	1144	1147	288
O	1147	1148	;
O	1149	1161	capecitabine
O	1161	1162	,
B-intervention-participants	1163	1166	297
O	1166	1167	)
O	1167	1168	.

O	1169	1175	Median
O	1176	1182	follow
O	1182	1183	-
O	1183	1185	up
O	1186	1189	was
O	1190	1192	67
O	1193	1199	months
O	1199	1200	.

O	1201	1204	The
B-outcome	1205	1206	5
I-outcome	1206	1207	-
I-outcome	1207	1211	year
I-outcome	1212	1215	DFS
I-outcome	1216	1220	rate
O	1221	1224	was
O	1225	1231	higher
O	1232	1235	for
O	1236	1248	capecitabine
O	1249	1253	than
O	1254	1257	for
O	1258	1265	control
O	1266	1275	treatment
O	1276	1277	(
B-iv-bin-percent	1277	1279	86
I-iv-bin-percent	1279	1280	.
I-iv-bin-percent	1280	1281	3
I-iv-bin-percent	1281	1282	%
O	1283	1284	v
B-cv-bin-percent	1285	1287	80
I-cv-bin-percent	1287	1288	.
I-cv-bin-percent	1288	1289	4
I-cv-bin-percent	1289	1290	%
O	1290	1291	;
O	1292	1298	hazard
O	1299	1304	ratio
O	1304	1305	,
O	1306	1307	0
O	1307	1308	.
O	1308	1310	66
O	1310	1311	;
O	1312	1314	95
O	1314	1315	%
O	1316	1318	CI
O	1318	1319	,
O	1320	1321	0
O	1321	1322	.
O	1322	1324	44
O	1325	1327	to
O	1328	1329	0
O	1329	1330	.
O	1330	1332	99
O	1332	1333	;
O	1334	1335	P
O	1336	1337	=
O	1338	1339	.
O	1339	1342	044
O	1342	1343	)
O	1343	1344	.

B-outcome	1345	1349	Five
I-outcome	1349	1350	-
I-outcome	1350	1354	year
I-outcome	1355	1362	overall
I-outcome	1363	1371	survival
I-outcome	1372	1377	rates
O	1378	1382	were
O	1383	1394	numerically
O	1395	1401	higher
O	1402	1405	but
O	1406	1409	not
O	1410	1423	significantly
O	1424	1432	improved
O	1433	1434	(
O	1434	1446	capecitabine
O	1446	1447	,
B-iv-bin-percent	1448	1450	93
I-iv-bin-percent	1450	1451	.
I-iv-bin-percent	1451	1452	3
I-iv-bin-percent	1452	1453	%
O	1453	1454	;
O	1455	1462	control
O	1462	1463	,
B-cv-bin-percent	1464	1466	90
I-cv-bin-percent	1466	1467	.
I-cv-bin-percent	1467	1468	7
I-cv-bin-percent	1468	1469	%
O	1469	1470	)
O	1470	1471	.

O	1472	1479	Overall
O	1479	1480	,
B-iv-bin-percent	1481	1483	39
I-iv-bin-percent	1483	1484	.
I-iv-bin-percent	1484	1485	1
I-iv-bin-percent	1485	1486	%
O	1487	1489	of
O	1490	1498	patients
O	1499	1502	had
B-outcome	1503	1515	capecitabine
I-outcome	1516	1520	dose
I-outcome	1521	1531	reductions
O	1531	1532	,
O	1533	1536	and
B-iv-bin-percent	1537	1538	8
I-iv-bin-percent	1538	1539	.
I-iv-bin-percent	1539	1540	4
I-iv-bin-percent	1540	1541	%
O	1542	1550	reported
B-outcome	1551	1556	grade
I-outcome	1557	1558	≥
I-outcome	1559	1560	3
I-outcome	1561	1565	hand
I-outcome	1565	1566	-
I-outcome	1566	1570	foot
I-outcome	1571	1579	syndrome
O	1579	1580	.

O	1581	1584	The
O	1585	1589	most
O	1590	1596	common
O	1597	1602	grade
O	1603	1604	≥
O	1605	1606	3
O	1607	1618	hematologic
O	1619	1629	toxicities
O	1630	1634	were
B-outcome	1635	1646	neutropenia
O	1647	1648	(
O	1648	1660	capecitabine
O	1660	1661	,
B-iv-bin-abs	1662	1665	136
O	1666	1667	[
B-iv-bin-percent	1667	1669	45
I-iv-bin-percent	1669	1670	.
I-iv-bin-percent	1670	1671	8
I-iv-bin-percent	1671	1672	%
O	1672	1673	]
O	1673	1674	;
O	1675	1682	control
O	1682	1683	,
B-cv-bin-abs	1684	1687	118
O	1688	1689	[
B-cv-bin-percent	1689	1691	41
I-cv-bin-percent	1691	1692	.
I-cv-bin-percent	1692	1693	0
I-cv-bin-percent	1693	1694	%
O	1694	1695	]
O	1695	1696	)
O	1697	1700	and
B-outcome	1701	1708	febrile
I-outcome	1709	1720	neutropenia
O	1721	1722	(
O	1722	1734	capecitabine
O	1734	1735	,
B-iv-bin-abs	1736	1738	50
O	1739	1740	[
B-iv-bin-percent	1740	1742	16
I-iv-bin-percent	1742	1743	.
I-iv-bin-percent	1743	1744	8
I-iv-bin-percent	1744	1745	%
O	1745	1746	]
O	1746	1747	;
O	1748	1755	control
O	1755	1756	,
B-cv-bin-abs	1757	1759	46
O	1760	1761	[
B-cv-bin-percent	1761	1763	16
I-cv-bin-percent	1763	1764	.
I-cv-bin-percent	1764	1765	0
I-cv-bin-percent	1765	1766	%
O	1766	1767	]
O	1767	1768	)
O	1768	1769	.

O	1770	1776	Safety
O	1777	1781	data
O	1782	1786	were
O	1787	1794	similar
O	1795	1797	to
O	1798	1801	the
O	1802	1807	known
O	1808	1820	capecitabine
O	1821	1827	safety
O	1828	1835	profile
O	1836	1839	and
O	1840	1849	generally
O	1850	1860	comparable
O	1861	1868	between
O	1869	1873	arms
O	1873	1874	.

O	1875	1887	Capecitabine
O	1888	1892	when
O	1893	1898	added
O	1899	1901	to
O	1902	1903	3
O	1904	1910	cycles
O	1911	1913	of
O	1914	1923	docetaxel
O	1924	1932	followed
O	1933	1935	by
O	1936	1937	3
O	1938	1944	cycles
O	1945	1947	of
O	1948	1949	a
O	1950	1951	3
O	1951	1952	-
O	1952	1956	drug
O	1957	1970	anthracycline
O	1971	1982	combination
O	1983	1993	containing
O	1994	2006	capecitabine
O	2007	2014	instead
O	2015	2017	of
O	2018	2030	fluorouracil
O	2031	2044	significantly
O	2045	2053	improved
O	2054	2057	DFS
O	2058	2060	in
O	2061	2065	TNBC
O	2066	2073	without
O	2074	2077	new
O	2078	2084	safety
O	2085	2093	concerns
O	2093	2094	.
